(Staffordshire, UK) - As part of its ongoing work on biocompatibility and bioactivity of Hydroxyapatite (HA), Ceram, the materials technology company, has published a new white paper, ‘Multi-Substituted Hydroxyapatites and the Role They Can Play in Enhanced Bone Replacement Solutions’.
The white paper, whilst giving a brief introduction of the opportunities for synthetic HA (and associated structures) in bone replacement, focuses on substituted Hydroxyapatite. Some results from a recently completed study on multi-substituted HA - carried out to find out how mean ionic volume and charge impact on the yield of the crystalline HA – are discussed. All HA work reported is based on computer controlled wet precipitation production routes under mild conditions that should be scalable.
With their newly-patented technology, Ceram’s aim is to work with clients to develop HA with tailored bioactivity, both for bone replacement materials applications and for new drug delivery systems with tailored bio-application requirements.
The white paper is free to download at www.ceram.com/ha.
Ceram is an independent, international materials technology company that focuses on innovation, sustainability and quality assurance of materials.
Headquartered in Staffordshire, UK, and with approved laboratories around the world, Ceram solves product and process challenges across a range of materials to help clients improve performance, comply with regulations and develop their sustainability performance in order to gain a competitive advantage and increase profitability.
Ceram operates in a wide variety of sectors around the world.